Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Фаза 2
Прекращено
NCT05025423
| Заболевание | Mantle Cell Lymphoma |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
|---|
| Статус | Прекращено |
|---|
| Участники | 7 участн. |
|---|
| Вмешательство | Venetoclax Oral Tablet [Venclexta] |
|---|
| Дата начала | 21.06.2022 |
|---|
| Дата завершения | 14.05.2025 |
|---|
| Публикация результатов | 9.06.2026 |
|---|
Кратко
The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.
Overall Response Rate (ORR) After Four Cycles of Venetoclax and Rituximab.
120 days · Participants
| Venetoclax and Rituximab in Patients Over 60 Yrs Old With Previously Untreated Mantle Cell Lymphoma | 4 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.